TABLE 2.
Agents | Patients | AEx |
Cisplatin | 91 | 15 (16.5%) |
Carboplatin | 250 | 20 (8.0%) |
Etoposide | 124 | 7 (5.6%) |
Paclitaxel | 146 | 18 (12.3%) |
Vinorelbine | 51 | 10 (19.6%) |
Docetaxel | 19 | 6 (31.6%) |
Gemcitabine | 6 | 1 (16.7%) |
Vindesine | 17 | 1 (5.9%) |
UFT | 17 | 5 (29.4%) |
Platinum-based regimen | 341 | 35 (10.3%) |
Nonplatinum-based regimen# | 49 | 13 (26.5%) |
UFT: tegafur-uracil. #: gefitinib was excluded.